Embecta Corp. (EMBC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Embecta Corp. (EMBC) regarding potential corporate wrongdoing. The firm is encouraging Embecta shareholders who purchased securities before November 25, 2026, and still hold them, to contact them to assist in the investigation. The firm operates on a contingency fee basis, aiming to recover investor capital through securities fraud class actions and shareholder derivative suits.
EMBECTA CORP. (NASDAQ: EMBC) SHAREHOLDER INVESTIGATION
Bernstein Liebhard LLP has announced an investigation into potential breaches of fiduciary duty by directors and officers of Embecta Corp. (NASDAQ: EMBC). The law firm is seeking to determine if the company's leadership fulfilled its obligations to shareholders, particularly for those who purchased shares before November 25, 2025. Shareholders are encouraged to contact Bernstein Liebhard for more information regarding their legal rights.
EMBECTA CORP. (NASDAQ: EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Bernstein Liebhard LLP has announced an investigation into Embecta Corp. (NASDAQ: EMBC) regarding potential breaches of fiduciary duty by its directors and officers. The firm is seeking to determine if the company's leadership acted in the best interests of shareholders, particularly those who owned shares before November 25, 2025. Shareholders are encouraged to contact Bernstein Liebhard for more information about their legal rights.
Bronstein, Gewirtz & Grossman, LLC Encourages Embecta Corp. (EMBC) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Embecta Corp. (NASDAQ:EMBC) securities who bought prior to November 25, 2026, and continue to hold them. The investigation focuses on whether Embecta and its officers/directors engaged in corporate wrongdoing. The firm encourages affected investors to contact them for more information, emphasizing that they represent investors on a contingency fee basis.
EMBECTA CORP. (NASDAQ: EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Bernstein Liebhard LLP has announced an investigation into potential breaches of fiduciary duty by certain directors and officers of Embecta Corp. (NASDAQ: EMBC). The investigation seeks to determine if the company's leadership fulfilled its obligations to shareholders and if legal remedies are available. Current Embecta shareholders who purchased shares before November 2, 2022, are encouraged to contact the firm for more information.
Bronstein, Gewirtz & Grossman, LLC Encourages Embecta Corp. (EMBC) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Embecta Corp. (EMBC) securities. The investigation concerns alleged corporate wrongdoing by Embecta and its officers/directors. The firm encourages Embecta stockholders who purchased securities prior to November 25, 2026, and still hold them, to contact them to assist with the investigation.
Embecta (EMBC) Earnings Date and Reports 2026
Embecta announced its Q3 2026 earnings, reporting an EPS of $0.56, which surpassed analyst estimates of $0.27. Despite an 8.1% year-over-year decrease in revenue to $271.70 million, it still exceeded the consensus estimate. The company's next earnings report is estimated for November 24, 2026, and earnings are projected to decrease by 4.35% next year.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Embecta Corp. (EMBC) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has announced an investigation into Embecta Corp. (EMBC) regarding potential corporate wrongdoing by its officers and directors. The firm encourages shareholders who purchased Embecta securities before November 25, 2026, and still hold them, to learn more and assist the investigation. The firm operates on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
Embecta Corp. (EMBC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Embecta Corp. (NASDAQ:EMBC) concerning potential corporate wrongdoing by the company and its officers/directors. The firm is encouraging investors who purchased Embecta securities before November 25, 2026, and continue to hold them, to contact them to assist with the investigation. The law firm operates on a contingency fee basis, meaning investors incur no upfront costs.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Embecta Corp. (EMBC) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Embecta Corp. (NASDAQ:EMBC) on behalf of investors who purchased securities prior to November 25, 2026. The investigation focuses on whether the company's officers and/or directors engaged in corporate wrongdoing. Investors are encouraged to visit the firm's website or contact them for more information at no cost.
Embecta director Milton Mayo sells $36,971 in shares By Investing.com
Embecta Corp. director Milton Mayo Morris sold 6,293 shares of company stock for $36,971 on September 4, 2026, at $5.875 per share. This sale occurred despite the stock appearing undervalued by InvestingPro analysis and recent positive fiscal Q3 2026 results where Embecta exceeded analyst expectations for earnings and revenue. Following the transaction, Mr. Morris still holds over 53,828 shares of Embecta.
Embecta director Milton Mayo sells $36,971 in shares
Embecta director Milton Mayo Morris sold 6,293 shares of the company's common stock for $36,971 on September 4, 2026. This transaction occurred at $5.875 per share, slightly above the current stock price, and follows a 61% decline in Embecta's shares over the past year, despite recent gains. The sale comes after Embecta reported strong fiscal third-quarter results, exceeding revenue and earnings expectations, and raising its full-year operating margin guidance.
Embecta director Milton Mayo sells $36,971 in shares
Embecta director Milton Mayo Morris sold 6,293 shares of the company's common stock for $36,971 on September 4, 2026. The sale occurred at $5.875 per share, while the stock currently trades at $5.55. Despite a 61% decline over the past year, the stock has recently gained 6% and is considered undervalued by InvestingPro analysis.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Embecta Corp. (EMBC) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has announced an investigation into Embecta Corp. (NASDAQ:EMBC) regarding potential corporate wrongdoing by its officers and/or directors. The firm encourages investors who purchased Embecta securities before November 25, 2026, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
Embecta Corp. (EMBC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP has announced a securities fraud class action lawsuit against Embecta Corp. (EMBC) for investors who suffered losses between November 25, 2025, and May 4, 2026. The lawsuit alleges that Embecta made misleading statements regarding its guidance and failed to disclose weaknesses in its business, particularly in the U.S. pen needle market. Investors who wish to serve as lead plaintiff must contact the law firm by August 17, 2026.
Embecta (NASDAQ: EMBC) director files to sell $36,891 in stock
Embecta Corp. director Morris Milton Mayo has filed a Form 144 to sell 6,293 common shares, valued at $36,891. These shares were acquired as director compensation on February 7, 2024. The filing indicates a neutral impact and sentiment on the company's stock.
embecta to Participate in Investor Events
Embecta Corp. (Nasdaq: EMBC) announced its participation in upcoming investor events, including the Wells Fargo 2026 Healthcare Conference and the J.P. Morgan 4th Annual Nashville Healthcare Conference 2026. Management will host one-on-one meetings and a fireside chat to discuss the company's progress in advancing its legacy in insulin delivery and becoming a broad-based medical supplies company.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Embecta Corp. (EMBC) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Embecta Corp. (EMBC) on behalf of investors who purchased securities before November 25, 2026, and continue to hold them. The investigation focuses on whether Embecta and its officers engaged in corporate wrongdoing. The firm encourages stockholders to connect with them for more information and to assist in the investigation, noting that they represent investors on a contingency fee basis.
Embecta: Excellent Turnaround Prospect In Defensive Medical Products
Embecta (EMBC) presents a compelling deep-value opportunity in defensive medical products, trading at a P/E below 3x and a free cash flow yield over 50%. Despite some sales decline and high debt, its high gross margins and market leadership support a bullish 12-month target of $8-10 per share. Technical momentum, insider buying, and high short interest suggest a potential sharp rebound if fundamentals stabilize, with takeover potential adding to its appeal.
EMBC Deadline Alert: The Gross Law Firm Reminds Embecta Corp. (EMBC) Investors of Securities Class Action Deadline on August 17, 2026
The Gross Law Firm has issued a notice reminding Embecta Corp. (NASDAQ: EMBC) investors of the securities class action deadline on August 17, 2026. The lawsuit alleges that Embecta made misleading statements about its fiscal results, particularly concerning its pen needle business, leading to a significant stock price drop after the company missed Q2 2026 guidance and lowered its full-year outlook. Shareholders who purchased EMBC shares between November 25, 2025, and May 4, 2026, are encouraged to contact the firm regarding lead plaintiff appointment.
EMBC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Embecta Corp. (NASDAQ:EMBC) for alleged federal securities law violations. The lawsuit claims Embecta made materially false and misleading statements regarding its business and prospects, particularly concerning its pen needle business and fiscal guidance. Investors who suffered losses between November 25, 2025, and May 4, 2026, have an opportunity to lead the class action lawsuit, with a deadline of August 17, 2026, to request appointment as lead plaintiff.
Price to book forward of Embecta Corporation – HAM:JX7
This article provides financial data for Embecta Corporation (HAM:JX7) on the Hamburg Stock Exchange, specifically focusing on its "Price to book forward" metric. The content highlights the stock's market status as closed with no trades and indicates that detailed financial information is available.
EMBECTA CORP. (EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Bernstein Liebhard LLP is investigating potential breaches of fiduciary duty by certain directors and officers of Embecta Corp. (NASDAQ: EMBC). The investigation aims to determine if the Company's leadership acted in the best interests of shareholders and if legal remedies are available. Shareholders who purchased shares before November 25, 2025, are encouraged to contact the firm for more information.
EMBC Deadline: EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit
The Rosen Law Firm reminds investors who purchased Embecta Corp. (NASDAQ: EMBC) common stock between November 25, 2025, and May 4, 2026, of the August 17, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Embecta made false or misleading statements regarding its fiscal results and guidance, particularly concerning its pen needle business, leading to investor damages. Investors are encouraged to contact the firm to join the class action.
EMBC Stock News: Embecta Sued for Securities Fraud over Alleged Misrepresentations and Corresponding 57% Stock Drop
Embecta Corp. (EMBC) is facing a securities fraud class action lawsuit filed by Bleichmar Fonti & Auld LLP. The lawsuit alleges that Embecta misled investors about the strength of its insulin pen needle product category, leading to a 57.8% stock drop on May 5, 2026, after the company announced disappointing Q2 2026 results and reduced its quarterly dividend. Investors have until August 17, 2026, to seek to be appointed lead plaintiff in the case.
EMBC Stock News: Embecta Sued for Securities Fraud over Alleged Misrepresentations and Corresponding 57% Stock Drop
Embecta Corp. (NASDAQ: EMBC) is being sued for securities fraud after its stock dropped over 57% due to alleged misrepresentations about the strength of its insulin pen needle product category. A class action lawsuit has been filed, claiming the company failed to disclose significant competition and market softness despite touting the product's resilience. The lawsuit follows Embecta's Q2 2026 results, which revealed a substantial share loss and a reduction in its quarterly dividend.
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026
Faruqi & Faruqi, LLP is reminding Embecta (EMBC) investors that the deadline to seek lead plaintiff status in a federal securities class action lawsuit is August 17, 2026. The lawsuit alleges that Embecta made misleading statements regarding its financial guidance and pen needle business, which led to a significant stock price drop of over 57.8% on May 5, 2026, after the company missed its second-quarter guidance and lowered its fiscal year 2026 outlook. Investors who purchased EMBC securities between November 25, 2025, and May 4, 2026, are encouraged to contact the law firm to discuss their legal options.
Bronstein, Gewirtz & Grossman LLC Urges Embecta Corp. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who purchased securities between November 25, 2025, and May 4, 2026. The lawsuit alleges that Embecta made materially false and misleading statements, particularly regarding its financial guidance and pen needle business, leading to investor harm. The firm is encouraging affected investors to join the case before the lead plaintiff deadline of August 17, 2026.
EMBC Deadline: EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit
The Rosen Law Firm is reminding investors who purchased Embecta Corp. (NASDAQ: EMBC) common stock between November 25, 2025, and May 4, 2026, about the August 17, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Embecta made misleading statements regarding its fiscal results and guidance, particularly concerning its pen needle business, leading to investor damages when the true details emerged. Investors are encouraged to contact the firm to potentially join the class action and act as lead plaintiff.
EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS) has announced a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) for alleged securities fraud, encouraging investors who purchased shares between November 25, 2025, and May 4, 2026, to contact the firm regarding lead plaintiff appointments. The lawsuit claims Embecta made misleading statements about its fiscal guidance, failing to disclose known headwinds in the pen needle market that would impact its performance. Investors who suffered losses have until August 17, 2026, to participate in the case.
Bronstein, Gewirtz & Grossman LLC Urges Embecta Corp. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who purchased securities between November 25, 2025, and May 4, 2026. The lawsuit alleges that Embecta made materially false and misleading statements, particularly regarding its pen needle business and financial guidance, leading to investor harm. Investors are encouraged to join the case by visiting the firm's website or contacting them, with a lead plaintiff deadline of August 17, 2026.
EMBC Court News: Embecta Securities Fraud Class Action
A securities fraud class action lawsuit has been filed against Embecta Corp. (NASDAQ: EMBC) and its executives due to a significant stock drop of over 57%. This drop followed the company allegedly misleading investors about the strength of its insulin pen needle product category, facing market softness and increased competition. Investors have until August 17, 2026, to apply to be lead plaintiffs in the lawsuit.
Embecta Corp. Sued for Securities Law Violations - FINAL DEADLINE TODAY - EMBC
DJS Law Group reminds investors of a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) for alleged securities law violations between November 25, 2025, and May 4, 2026. The lawsuit claims Embecta made false and misleading statements regarding its fiscal guidance despite being aware of challenges in the pen needle market. Investors who suffered losses and purchased shares during this period are encouraged to contact DJS Law Group by the final deadline, August 17, 2026, to potentially participate in the lawsuit.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026
Faruqi & Faruqi, LLP is reminding Embecta (EMBC) investors of an approaching securities class action lawsuit deadline on August 17, 2026. The lawsuit alleges that Embecta made false and misleading statements regarding its financial performance, specifically its pen needle business, which led to a significant stock price drop on May 5, 2026. Investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, are encouraged to contact the law firm to discuss their legal options or to seek appointment as lead plaintiff.
Embecta Corp. (EMBC) Notice of August 17, 2026 Deadline in Class Action Lawsuit – Hagens Berman
Hagens Berman is investigating Embecta Corp. (EMBC) following a class action lawsuit alleging the company misrepresented the stability of its insulin pen needle business, leading to substantial investor losses. The lawsuit claims Embecta's assurances of a "stable" business were false, as the company faced significant competitive share loss and market volume softness, culminating in a massive revenue decline, a 43% cut in EPS guidance, and a 93% dividend reduction, causing a 57.8% stock plummet. Investors who purchased EMBC stock between November 25, 2025, and May 4, 2026, are encouraged to contact Hagens Berman by the August 17, 2026 deadline.
Kaplan Fox Continues to Remind Embecta Corp. (NASDAQ: EMBC) Investors of the Lead Plaintiff Deadline on August 17, 2026
Kaplan Fox & Kilsheimer LLP is reminding investors of Embecta Corp. (NASDAQ: EMBC) that the lead plaintiff deadline for a class action lawsuit is August 17, 2026. The lawsuit, filed on behalf of investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, alleges that the company's management knew about segment weakness, particularly in the U.S. pen needle market, that would impact its revenue guidance and Q2 2026 results. This follows a significant drop in Embecta's stock price after it reported disappointing Q2 2026 financial results and reduced its fiscal 2026 revenue guidance.
Bronstein, Gewirtz & Grossman LLC Urges Embecta Corp. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has announced a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) and its officers, alleging violations of federal securities laws. The lawsuit claims that Embecta made false and misleading statements regarding its business, operations, and prospects between November 25, 2025, and May 4, 2026, specifically concerning its pen needle business and financial guidance. Investors who suffered losses are encouraged to join the case, with a lead plaintiff deadline of August 17, 2026.
Kaplan Fox Continues to Remind Embecta Corp. (NASDAQ: EMBC) Investors of the Lead Plaintiff Deadline on August 17, 2026
Kaplan Fox & Kilsheimer LLP is reminding investors of the upcoming lead plaintiff deadline, August 17, 2026, in a class action lawsuit against Embecta Corp. The lawsuit, filed on behalf of investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, alleges that the company misrepresented its financial outlook. This reminder follows a significant drop in Embecta's stock price after it reported disappointing Q2 2026 financial results and reduced its fiscal 2026 revenue guidance.
CLASS ACTION DEADLINE MONDAY NIGHT: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026
Faruqi & Faruqi, LLP is reminding Embecta (EMBC) investors of the August 17, 2026, deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that Embecta made misleading statements regarding its financial guidance, particularly concerning its pen needle business, leading to a significant stock price drop on May 5, 2026. Investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, are encouraged to contact the firm to discuss their legal options.
EMBECTA CORP. DEADLINE MONDAY AUGUST 17th: Embecta Corp.
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who purchased common stock between November 25, 2025, and May 4, 2026. The lawsuit alleges that Embecta made misleading statements regarding its fiscal results, particularly its pen needle business, leading to a significant stock price drop after the company cut its 2026 fiscal guidance. Investors have until August 17, 2026, to apply to be appointed as lead plaintiff.
EMBC Shareholder Alert: August 17, 2026 Lead Plaintiff Deadline in Embecta Corp. Securities Class Action - Contact The Gross Law Firm
The Gross Law Firm has issued a shareholder alert regarding a securities class action against Embecta Corp. (NASDAQ: EMBC). Shareholders who purchased EMBC shares between November 25, 2025, and May 4, 2026, are encouraged to contact the firm, as the company is accused of making misleading statements about its financial health, specifically its pen needle business, prior to a significant stock price drop. The deadline to apply for lead plaintiff status is August 17, 2026.
Kaplan Fox Alerts Embecta Corp. (NASDAQ: EMBC) Investors Who Suffered Losses to a Securities Class Action – Deadline is August 17, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who purchased securities between November 25, 2025, and May 4, 2026. The lawsuit stems from Embecta's Q2 2026 financial results, which were significantly below expectations, leading to a over 57% drop in stock price. Investors who suffered losses have until August 17, 2026, to move the court to serve as a lead plaintiff.
Embecta Corp. SVP Elguicze purchases $93,360 in common stock
Embecta Corp.'s Senior Vice President and CFO, Jacob Elguicze, recently purchased 20,000 shares of the company's common stock for $93,360. This insider purchase comes after a significant stock decline but a recent rebound, with the company trading at a low P/E ratio. The purchase follows strong Q3 fiscal 2026 results where Embecta exceeded analyst expectations for earnings and revenue, and raised its full-year guidance.
Insider Spends US$141k Buying More Shares In Embecta
Embecta's President, Devdatt Kurdikar, recently purchased US$141k worth of company stock at US$4.70 per share, increasing his holding by 3.9%. This is the largest insider purchase in the last year, suggesting optimism for the company's future, despite the overall insider ownership being relatively low at 1.6%. The article highlights that while insider ownership levels are modest, the recent buying activity indicates reasonable alignment and a positive outlook from insiders.
Bronstein, Gewirtz & Grossman LLC Urges Embecta Corp. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) and its officers, alleging violations of federal securities laws. The lawsuit claims that Embecta made misleading statements regarding its business, operations, and prospects, specifically concerning its pen needle business and fiscal guidance, leading to investor harm. Investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, are encouraged to join the class action by August 17, 2026.
Kaplan Fox Continues to Alert Investors of Embecta Corp. (NASDAQ: EMBC) to a Class Action Deadline on August 17, 2026
Kaplan Fox & Kilsheimer LLP is alerting investors of Embecta Corp. (NASDAQ: EMBC) about a class action lawsuit filed against the company. The lawsuit, on behalf of investors who purchased securities between November 25, 2025, and May 4, 2026, alleges that Embecta misrepresented its financial outlook, leading to a significant stock drop after disappointing Q2 2026 results. Investors have until August 17, 2026, to move for lead plaintiff status.
Kaplan Fox Continues to Alert Investors of Embecta Corp. (NASDAQ: EMBC) to a Class Action Deadline on August 17, 2026
Kaplan Fox & Kilsheimer LLP is alerting investors of Embecta Corp. (NASDAQ: EMBC) to a class action lawsuit with a lead plaintiff deadline of August 17, 2026. The lawsuit alleges that Embecta made misleading statements regarding its financial outlook, particularly concerning weakness in the U.S. pen needle market, which led to a significant drop in stock price after disappointing Q2 2026 results were announced. Investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, are encouraged to contact the firm.
EMBC 4-DAY DEADLINE ALERT: Embecta Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Hagens Berman
Hagens Berman is investigating Embecta Corp. (NASDAQ: EMBC) for alleged violations of federal securities laws, following a class action lawsuit claiming the company misrepresented the stability of its insulin pen needle business. Investors who suffered substantial losses between November 25, 2025, and May 4, 2026, have until August 17, 2026, to seek to become lead plaintiff. The lawsuit alleges Embecta's assurances of a "stable" business were false, as the company experienced significant competitive share loss and market volume softness, leading to a massive revenue decline and a drastic cut in its full-year guidance and quarterly dividend.
EMBC Shareholder Alert: Embecta Corp. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt
SueWallSt has issued an alert to investors of Embecta Corp. (NASDAQ: EMBC) regarding a pending securities class action lawsuit. The lawsuit names CEO Devdatt Kurdikar and CFO Jacob P. Elguicze as individual defendants, alleging they disseminated misleading fiscal year 2026 guidance that caused shareholders to lose $5.35 per share. Investors who purchased EMBC shares between November 25, 2025, and May 4, 2026, are encouraged to contact SueWallSt, with a lead plaintiff deadline set for August 17, 2026.
EMBC Deadline: Rosen Law Firm Urges Embecta Corp. (NASDAQ: EMBC) Stockholders to Contact the Firm for Information About Their Rights
Rosen Law Firm has issued a reminder to investors regarding a class action lawsuit against Embecta Corp. (NASDAQ: EMBC). The lawsuit alleges that Embecta made misleading statements about its fiscal results and its pen needle business, causing investors to suffer damages. Shareholders who wish to act as lead plaintiff must file motions with the court by August 17, 2026.
